Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal
CompanyDeals

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that it has entered into a collaboration agreement with a partner for the Japan rights to its denosumab injection 60 mg (BA6101),…

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Hospital

Hengrui Pharmaceuticals-Backed Nanjing Tianyinshan Hospital Opens as Class 3A Oncology Specialist Center

CompanyDrug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Six Drugs in China and the US

CompanyDeals

CStone Pharmaceuticals Regains Exclusive Rights to Tibsovo in Greater China and Singapore

CompanyDrug

Sanofi Halts Development of Tusamitamab Ravtansine After Missed Trial Endpoints

Company

CStone Pharmaceuticals Disbands Sales Team for Gavreto After NRDL Setback

CompanyDrug

Sino Biopharmaceutical Completes Enrollment for Phase III Trial of Anlotinib in Soft Tissue Sarcoma

CompanyDrug

Legend Biotech’s Carvykti Therapy to Include Myeloid Neoplasms Warning in Label Update

CompanyDrug

AstraZeneca Advances to Phase III with PD-1xTIGIT BsAb for Biliary Tract Cancer

Show More